SAB Biotherapeutics, Inc.
SABS · NASDAQ
Bulios Fair Price
$2.92
12.8% downside
Trenutna cena
$3.35
Po podatkih Bulios Fair Price je delnica SABS trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
SAB Biotherapeutics, Inc. is a biotechnology company based in the United States, specializing in the development and production of monoclonal antibodies for the treatment of various diseases. Their platform utilizes transchromosomal production technology to create monoclonal antibodies using genetically modified animal production systems. These antibodies have a wide range of applications in the treatment of oncological, infectious, and autoimmune diseases. SAB Biotherapeutics focuses on innovative solutions in drug development and therapies aimed at improving human health. Shares of SAB Biotherapeutics, Inc. could be an interesting investment opportunity for investors following the biotechnology sector and seeking innovative and promising companies in drug development.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Samuel J. Reich
Employees
86
Headquarters
Miami Beach
Prihajajoči dogodki
Earnings
Upcoming earnings report